Oxaliplatine Sun

Oxaliplatin, the active ingredient in Oxaliplatine Sun, is a platinum compound (alkylating-like agent) presented as a solution for injection for intravenous use. It is employed in the adjuvant treatment of stage III colon cancer and as first‑line therapy for metastatic colorectal cancer in adult patients. GNH USA supplies Oxaliplatine Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Oxaliplatine Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Oxaliplatin is used in colorectal cancer treatment pathways, providing cytotoxic therapy for specific disease stages.

- Stage III colon cancer (adjuvant): Improves disease‑free survival after surgical resection. - Metastatic colorectal cancer (first‑line): Reduces tumor burden and prolongs overall survival. - Combination regimens (e.g., FOLFOX): Enhances efficacy when paired with fluoropyrimidines and leucovorin.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects: - Peripheral neuropathy: tingling or numbness, often dose‑related. - Nausea and vomiting: may occur during or after infusion. - Diarrhea: watery stools, sometimes requiring antidiarrheal medication. - Fatigue: generalized tiredness during treatment cycles. - Myelosuppression: reduced blood cell counts, increasing infection risk. - Elevated liver enzymes: mild transaminase rise detected in labs.

Serious or Rare Side Effects: - Severe neuropathy: persistent loss of sensation that may be irreversible. - Acute allergic reactions: rash, bronchospasm, or anaphylaxis during infusion. - Hemolytic anemia: destruction of red blood cells. - Cardiotoxicity: rare heart rhythm disturbances. - Severe neutropenia or thrombocytopenia: markedly low white‑cell or platelet counts. - Renal impairment: acute kidney injury in susceptible patients.

Before initiating Oxaliplatin therapy, clinicians should assess patient suitability and monitor for known risks.

- Renal function: evaluate creatinine clearance and adjust if impaired. - Hepatic function: check liver enzymes and bilirubin levels. - Pre‑existing neuropathy: consider alternative regimens if significant. - Hematologic status: obtain baseline complete blood count. - Pregnancy and lactation: avoid use; discuss risks with a specialist. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin may interact with other agents, influencing efficacy or toxicity. Monitoring and dose adjustments are often required.

Major Interactions (Avoid): - Nephrotoxic drugs (e.g., cisplatin, aminoglycosides): increase risk of kidney injury. - Myelosuppressive agents (e.g., high‑dose cyclophosphamide): exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may affect oxaliplatin clearance. - Calcium and magnesium infusions: can reduce neurotoxicity but require timing coordination. - Warfarin: potential alteration of INR values. - NSAIDs: may worsen renal function when combined. - Proton pump inhibitors: possible impact on drug absorption dynamics.